REG - Oxford Nanopore Tech - Daniel Mahony appointed as Non-Executive Director

Oxford Nanopore TechnologiesAnnouncement

01/10/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241001:nRSA3390Ga&default-theme=true

RNS Number : 3390G  Oxford Nanopore Technologies plc  01 October 2024

1 October 2024

 

 
Oxford Nanopore Technologies plc

                                    Dr
Daniel Mahony appointed as Non-Executive Director

 

Oxford Nanopore Technologies plc (LSE: ONT) (''Oxford Nanopore'' or ''the
Group''), the company delivering a new generation of nanopore-based molecular
sensing technology, is pleased to announce that Dr Daniel Mahony will be
joining the Group as a Non-Executive Director with effect from 1 October 2024.

Daniel brings extensive sector experience to help accelerate Oxford Nanopore's
commercial traction, with more than 25 years as a global healthcare investor
specialising in biotechnology, medical technology and healthcare services. As
Senior Partner in Growth Investments at Novo Holdings, Daniel will serve as a
critical sounding board to the Group as it continues to advance its technology
platform to address a significant commercial opportunity in
biopharmaceuticals. In addition, he currently chairs the UK BioIndustry
Association and is a Non-Executive Director of the Wellcome Sanger Institute.

Prior to joining Novo Holdings, Daniel co-founded the healthcare business unit
at Polar Capital in London, growing it to more than $4 billion in assets under
management. He was formerly a Senior Research Analyst at Morgan Stanley in
London, an Analyst at ING Barings Furman Selz in New York, and completed his
postdoctoral work at DNAX Research Institute in Palo Alto.

Dr Guy Harmelin, a non-executive director of the Group, who has served on the
Board since 2020, has informed the Board of his intention to step down from
the Board with effect from today. Dr Guy Harmelin, is stepping down to focus
on various other Directorship responsibilities.

Duncan Tatton-Brown, Chair of Oxford Nanopore, said: "We are extremely pleased
to welcome Daniel to the board as Non-Executive Director of Oxford Nanopore.
Daniel's deep knowledge of the biopharma sector, combined with his
understanding of Oxford Nanopore's opportunity to drive value across the
biopharma development pipeline, position him as an ideal source of expertise
to support the company's commercial expansion into this space. I would like to
thank Guy, our outgoing non-executive director for his outstanding support
overall and contribution in helping the Group transition from a private to a
public company during his tenure."

Dr Daniel Mahony, incoming Non-Executive Director of Oxford Nanopore, said:
"This is an exciting time for Oxford Nanopore with its expanding opportunity
in biopharma, where rapid sequencing, richer data and a streamlined platform
can support discovery and delivery of new biopharmaceuticals. I look forward
to bringing my industry expertise to bear as Oxford Nanopore executes against
its exciting growth plans in this sector."

Dr Gordon Sanghera, Chief Executive Officer of Oxford Nanopore, said: "Daniel
brings substantial strategic experience to support Oxford Nanopore's
commercial growth in the life sciences and specifically the biopharma market.
His perspectives will be invaluable as we continue to expand the use of our
technology to address the needs of this industry, and I look forward to
working with Daniel as we enter this next phase. I also would like to thank
Guy, our outgoing non-executive director, for his insight and guidance during
his tenure on the board. We appreciate his significant contribution and wish
him well in his next chapter."

Novo Holdings is a shareholder in Oxford Nanopore and led the recent £80
million equity placing. The decision to appoint Dr Mahony to the Board of
Oxford Nanopore reflects his considerable industry expertise and the value he
brings to the Board.

This announcement is made pursuant to Listing Rule 9.6.11R.  There are no
other details required to be disclosed under Listing Rule 9.6.13R.

 

-ENDS-

For further information, please contact:

Oxford Nanopore Technologies plc

Investors:         ir@nanoporetech.com (mailto:ir@nanoporetech.com)

Media:              media@nanoporetech.com
(mailto:media@nanoporetech.com)

 

Teneo (communications adviser to the Group)

Tom Murray, Olivia Peters

+44 (0) 20 7353 4200

OxfordNanoporeTechnologies@teneo.com

About Oxford Nanopore Technologies plc:

Oxford Nanopore Technologies' goal is to bring the widest benefits to society
through enabling the analysis of anything, by anyone, anywhere. The Group has
developed a new generation of nanopore-based sensing technology that is
currently used for real-time, high-performance, accessible, and scalable
analysis of DNA and RNA. The technology is used in more than 125 countries,
to understand the biology of humans, plants, animals, bacteria, viruses and
environments as well as to understand diseases such as cancer.  Oxford
Nanopore's technology also has the potential to provide broad, high impact,
rapid insights in a number of areas including healthcare, food and
agriculture.

For more information please visit: www.nanoporetech.com
(http://www.nanoporetech.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAEAXNEDDKLEFA